The discovery of genetic alterations of CDKN2A as well as other cell cycle regulators in breast cancers has led to the approval of CDK4/6 inhibitors (palbociclib) for the treatment of ER+/HER2‐ advanced/metastatic breast carcinomas.10, 11. Here, CDKN2A is linked to breast carcinoma.